McLaren Health Care Faces IT and Telephone Systems Disruptionby Lilu Anderson 07.08.2024McLaren Health Care is experiencing IT and phone system outages, impacting patient services. The health system is working to resolve ...
Amgen’s Q2 Revenue Rises 20% Despite Higher Expensesby Mark Eisenberg 07.08.2024Amgen's Q2 profit drops due to higher expenses, but revenue sees a 20% increase, driven by Horizon acquisition.
Novo Nordisk’s $4.1B Clayton Facility to Add 1,000 Jobsby Mark Eisenberg 25.06.2024Novo Nordisk's $4.1B Clayton investment creates 1,000 jobs, boosts local economy, and enhances life science growth in North Carolina.
ResMed, Inspire Medical Drop After Lilly’s Zepbound Studyby Mark Eisenberg 24.06.2024"ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
Sharps Technology vs. Competitors: A Profitability Reviewby Lilu Anderson 23.06.2024"Sharps Technology (STSS) vs. Competitors: A review of profitability, ownership, volatility, ratings, and valuation in the medical device sector."
Jazz’s Midphase Tremor Drug Misses Mark, Future Uncertainby Lilu Anderson 20.06.2024Jazz Pharmaceuticals hits a hurdle as its essential tremor drug trial misses primary endpoint. Awaiting Parkinson's trial results for future ...
Iontronic Tech Promises Hope in Slowing Malignant Brain Tumorsby Lilu Anderson 20.06.2024"Iontronic tech shows promise in slowing malignant brain tumor growth by continuously delivering low-dose drugs, bypassing the blood-brain barrier."
Biotech’s Big Gamble Fails: Insights and Implicationsby Lilu Anderson 18.06.2024Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Biotech’s Big Gamble Fails: Insights and Implicationsby Lilu Anderson 18.06.2024Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Madrigal Pharma Exec Sells $570K in Stock Amid Analyst Focusby Mark Eisenberg 15.06.2024Waltermire sells 2,000 shares at $285 each, netting $570K; Madrigal Pharmaceuticals sees mixed analyst reports with H.C. Wainwright lowering its ...